CClinicalTrials.gg
CompletedNCT05362396Updated Sep 2, 2022

Inspiratory Muscle Training With Powerbreath Device in Patients With Fibromyalgia

An interventional study of Inspiratory Muscle Training with Powerbreath IMT device. in Fibromyalgia, sponsored by Universidad Francisco de Vitoria. Completed at 1 site in Spain. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Universidad Francisco de Vitoria · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

Context/background: people affected by fibromyalgia see their own life totally disturbed after the diagnosis. This disease also courses, apart from the functional and depressing worsening, with internal damage manifested by a cardio respiratory deterioration. There are not many clinical studies publications about this disease given that is considered a weird illness with short prognosis.

Objectives: to examine the effects of the inspiratory muscle training (IMT) on respiratory muscle strength, lumbar pain, quality of life, phase angle and body composition in patients with Fibromyalgia.

The participants of experimental group will conduct 5 sets of 10 inspirations per day, 5 days per week, through 8 weeks.

Read the detailed description

Methods: 40 volunteer patients, female, with fibromyalgia will take part of the cuasi-experimental study and they will be divided into two groups: an experimental group (n = 20) and a control group (n = 20). The Maximum Inspiratory Pressure (PIM), the quality of life, lumbar pain, phase angle and body composition will be measured.

Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 inspirations, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP

After 8 weeks, all participants will fill up again all scales and post training measurements will be taken.

02

Conditions studied

03

In context

Fibromyalgia

1,336 studies on the registry are indexed under Fibromyalgia; 266 are open to participants now.

This study's enrollment of 40 is below the median of 60 across 1,035 interventional studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

Universidad Francisco de Vitoria is the lead sponsor of 52 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • subjects with fibromyalgia

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Inspiratory muscle training

    Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual

    Other: Inspiratory Muscle Training with Powerbreath IMT device.

  • No intervention
    No training program

    Without inspiratory muscle training. Treatment asusual.

Interventions

  • OtherInspiratory Muscle Training with Powerbreath IMT device.

    Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 repetitions, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP

06

What researchers measure

Primary outcomes

  1. MIP

    Maximum Inspiratory Pressure. Inspiratory muscle strength will be measured in % by a POWER-breathe device

    Time frame: Change from baseline inspiratory muscle strength at 8 weeks]

  2. Pain: Pressure algometry

    Pain will be measured with pressure algometry measured in Kg from 0 to 5kg.

    Time frame: 8 week

  3. Pain :VAS

    Visual Analogic Scale. Pain will be measured with a visual analog scale from 0 to 10. 0 points is no pain.

    Time frame: change from baseline after 8 week

  4. phase angle

    The phase angle, which is measured via bioelectrical impedance analysis (BIA), InBody 770 ,is a clinically important bioimpedance parameter used for nutritional assessment and evaluating the risk of various diseases. The phase angle was calculated automatically by the BIA device from these two components according to the following formula: phase angle (°) = (reactance/resistance) × (180°/π).

    Time frame: 8 week

  5. Fibromyalgia Impact Questionnaire (S-FIQ)

    The Fibromyalgia Impact Questionnaire (FIQ) is a brief 10-item, self-administered instrument that measures physical functioning, work status, depression, anxiety, sleep, pain, stiffness, fatigue, and well being. The total FIQ score is between 0-100. Thus, 0 represents the highest functional capacity and quality of life and 100 the worst state.

    Time frame: 8 week

  6. Diaphragm tickness

    Diaphragm muscle thickness will be measured in mm by an ultrasound device

    Time frame: Change from baseline diaphragm muscle thickness at 8 weeks

07

Study locations

1 site
  • Universidad Francisco de Vitoria
    Pozuelo De Alarcón, Madrid 28223, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05362396
Lead sponsor
Universidad Francisco de Vitoria
Responsible party
Sponsor
First posted
May 5, 2022
Start date
May 1, 2022
Primary completion
Aug 1, 2022
Completion
Sep 1, 2022
Last update
Sep 2, 2022

Study contacts

Davinia Vicente Campos, PhD
principal investigator · Universidad Francisco de Vitoria

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion